Oncology Frontier: What impression do you get from this CSCO conference?

 

　　Prof. Robinson: It is very large， a lot of good speakers， and a lot of enthusiastic people attending. I’ve only been to the one session in which I was a speaker and also have listened to other people speaking in the lung cancer session and it is well organized.

 

　　Oncology Frontier: At CSCO-CAHON-SITC Joint Symposium， you introduced a novel cancer immunotherapy approaches utilizing sequence-defined neo-antigens. How does the novel immunotherapy work?

　　Prof. Robinson: Well it is different to the current immunotherapy which removes the breaks of the immune system and allows whatever is happening to happen. But， neo-antigens directed therapy involves identifying the mutations in the cancer and making a vaccine in order to force the immune system to mount a strong attack against the cancer.

 

　　Oncology Frontier: Could you please talk about the research?progress?and clinical?application?prospect?of this new immunotherapy?

 

　　Prof. Robinson: We have been conducting experiments in animal models for about 3 years， and it has got to the point where we can effectively eradicate established squamous in mice with this therapy on the basis of that way we have written a protocol to begin a human clinical trial. That protocol is being completed and accepted but now it is going through the final stages of ethical approval. I think we will enroll our first patient by the end of this year or early next year. We will begin with lung cancer and then we hope to spend some years using this. I think the most widely road for this therapy will be in combination with other therapies particularly with checkpoint blockade， but probably also other therapies such as chemotherapy， selected chemotherapy.

 

 

　　Prof. Robinson: I am sure it will get stronger. As China continues to develop so quickly and with such beautiful conference facilities and increasingly high levels of medical attention， I think CSCO will probably become stronger. Also， China is developing its own biotechnology and other cancer related novel approaches. So， I am sure CSCO will be where new world first trials are presented as well. And that will be very exciting for everybody.
 

　　《肿瘤瞭望》：请您对这次CSCO会议有哪些印象？

 

　　Robinson教授：我感受到这次CSCO会议规模很大，组委会邀请了很多优秀的讲者，会议也吸引了很多热情的参会者。我目前还只参加了有我演讲的那个专题部分，我也听了肺癌专题其他专家的演讲，我认为这次会议组织得很好。

 

　　《肿瘤瞭望》：在CSCO-CAHON-SITC联合研讨会中，您介绍了一种新的肿瘤精准细胞免疫治疗手段，就是利用基于基因检测的癌细胞特异性新抗原。您是否可以向我们介绍一下这种新型免疫治疗是怎样发挥疗效的？

 

　　Robinson教授：首先，它不同于目前的免疫疗法，我们知道目前的免疫疗法是调节、改造人体自身的免疫系统，协同机体免疫系统杀伤肿瘤。然而，这种新型免疫疗法包括确定肿瘤中的基因突变，基于肿瘤患者基因检测，筛选可引起强烈免疫反应的新抗原，刺激免疫系统猛烈抗击肿瘤。

 

　　《肿瘤瞭望》：能否请您谈一谈这种新抗原免疫治疗的研究进展和临床应用前景？

 

　　Robinson教授：之前，我们已经进行了超过三年的动物实验研究，并且得到了一些有效的实验结果。基于此，我们已经起草了临床试验方案，准备开始临床试验。我们的临床试验方案已经完成并且被通过，目前正在进行临床伦理批准的最后阶段。我想我们将在今年年底或明年年初入组我们的第一个临床试验患者。我们会首先从肺癌入手，并且我们希望能够长期观察下去。对于它的临床应用前景，我想最有可能的是联合其他治疗，尤其是检查点阻断疗法，或许也可能联合其他治疗比如化疗和选择性化疗。

 

　　《肿瘤瞭望》：您对CSCO会议的未来有何期待？

 

　　Robinson教授：随着中国持续地迅猛发展，CSCO会议拥有众多如此美丽的会议举办地，以及对于医疗行业的不断关注，我相信CSCO会议一定会越办越好。此外，中国也在发展自己的生物技术和其他肿瘤相关的新型技术。因此，我相信CSCO会议将会是向世界展示这些成果的平台，这对于每个人都是激动人心的。

 

 

　　专家简介

　

 

　　澳大利亚珀斯的查尔斯·盖尔德纳爵士医院呼吸内科顾问医师、西澳大学医学院教授、澳大利亚石棉疾病研究中心（NCARD）主任；癌症基因组图谱(TCGA)计划、国际癌症基因组联盟(ICGC)间皮瘤测序计划的联合主席。

 

　　Robinson教授的团队首次发现肿瘤免疫治疗与化疗治疗的协同效应。